Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

被引：10

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Shallis, Rory M. ^{[2
,3
]}

Derkach, Andriy ^{[4
]}

Goldberg, Aaron D. ^{[1
]}

Stein, Anthony ^{[5
]}

Stein, Eytan M. ^{[1
]}

Marcucci, Guido ^{[5
]}

Zeidan, Amer M. ^{[2
,3
]}

Shimony, Shai ^{[6
]}

DeAngelo, Daniel J. ^{[6
]}

Stone, Richard M. ^{[6
]}

Aldoss, Ibrahim ^{[5
]}

Ball, Brian J. ^{[5
]}

Stahl, Maximilian ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[2] Yale Univ, New Haven, CT USA

[3] Yale Canc Ctr, New Haven, CT USA

[4] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA

[5] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[6] Dana Farber Canc Inst, Div Leukemia, Dept Med Oncol, Boston, MA 02115 USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Acute myeloid leukemia; AML; targeted agents; venetoclax; outcomes; AZACITIDINE; COMBINATION;

D O I：

10.1080/10428194.2022.2136952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with hypomethylating agents or low-dose cytarabine have expanded treatment options for patients with acute myeloid leukemia (AML). However, little data exist on the efficacy of venetoclax-based therapies in AML patients previously treated with FLT3 or IDH1/2 inhibitors. In this multicenter, retrospective cohort study, we included 44 patients who received venetoclax-based therapy after FLT3, IDH1 or IDH2 inhibitors. The overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 56.8% (18.2% CR) and a median overall survival of 9.2 months. While 6 out of 7 patients with IDH1 mutations who had previously been treated with ivosidenib responded to venetoclax-based therapy, FLT3-ITD mutations were associated with a lower response rate. Our data suggest that venetoclax can be an effective salvage therapy in patients previously treated with IDH1/2 or FLT3 inhibitors.

引用

页码：188 / 196

页数：9

共 18 条

[1] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia [J].

Abbott, Diana ;

Cherry, Evan ;

Amaya, Maria ;

McMahon, Christine ;

Schwartz, Marc ;

Winters, Amanda ;

Schowinsky, Jeffrey ;

Jordan, Craig T. ;

Smith, Clayton ;

Gutman, Jonathan A. ;

Pollyea, Daniel A. .

LEUKEMIA & LYMPHOMA, 2021, 62 (06) :1466-1473

[2] Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant [J].

Bewersdorf, Jan Philipp ;

Derkach, Andriy ;

Gowda, Lohith ;

Menghrajani, Kamal ;

DeWolf, Susan ;

Ruiz, Josel D. ;

Ponce, Doris M. ;

Shaffer, Brian C. ;

Tamari, Roni ;

Young, James W. ;

Jakubowski, Ann A. ;

Gyurkocza, Boglarka ;

Chan, Alexander ;

Xiao, Wenbin ;

Glass, Jacob ;

King, Amber C. ;

Cai, Sheng F. ;

Daniyan, Anthony ;

Famulare, Christopher ;

Cuello, Bernadette M. ;

Podoltsev, Nikolai A. ;

Roshal, Mikhail ;

Giralt, Sergio ;

Perales, Miguel-Angel ;

Seropian, Stuart ;

Cho, Christina ;

Zeidan, Amer M. ;

Prebet, Thomas ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Goldberg, Aaron D. ;

Stahl, Maximilian .

LEUKEMIA & LYMPHOMA, 2021, 62 (14) :3394-3401

[3] Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis [J].

Bewersdorf, Jan Philipp ;

Giri, Smith ;

Wang, Rong ;

Williams, Robert T. ;

Tallman, Martin S. ;

Zeidan, Amer M. ;

Stahl, Maximilian .

HAEMATOLOGICA, 2020, 105 (11) :2659-2663

[4] How I treat relapsed or refractory AML [J].

DeWolf, Susan ;

Tallman, Martin S. .

BLOOD, 2020, 136 (09) :1023-1032

[5] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[6] Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML [J].

DiNardo, C. D. ;

Tiong, I. S. ;

Quaglieri, A. ;

MacRaild, S. ;

Loghavi, S. ;

Brown, F. C. ;

Thijssen, R. ;

Pomilio, G. ;

Ivey, A. ;

Salmon, J. M. ;

Glytsou, C. ;

Fleming, S. A. ;

Zhang, Q. ;

Ma, H. ;

Patel, K. P. ;

Kornblau, S. M. ;

Xu, Z. ;

Chua, C. C. ;

Chen, Xufeng ;

Blombery, P. ;

Flensburg, C. ;

Cummings, N. ;

Aifantis, I. ;

Kantarjian, H. ;

Huang, D. C. S. ;

Roberts, A. W. ;

Majewski, I. J. ;

Konopleva, M. ;

Wei, A. H. .

BLOOD, 2020, 135 (11) :791-803

[7] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

[8] How I treat acute myeloid leukemia in the era of new drugs [J].

DiNardo, Courtney D. ;

Wei, Andrew H. .

BLOOD, 2020, 135 (02) :85-96

[9] Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies [J].

DiNardo, Courtney D. ;

Rausch, Caitlin R. ;

Benton, Christopher ;

Kadia, Tapan ;

Jain, Nitin ;

Pemmaraju, Naveen ;

Daver, Naval ;

Covert, Wendy ;

Marx, Kayleigh R. ;

Mace, Morgan ;

Jabbour, Elias ;

Cortes, Jorge ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Bhalla, Kapil N. ;

Kantarjian, Hagop ;

Konopleva, Marina .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) :401-407

[10] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

← 1 2 →